An Early Phase 1 interventional study of Aspirin and Placebo in Preeclampsia, sponsored by Anna Stanhewicz, PhD. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.
Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 47th largest by planned enrollment, is one of 7 that started in 2023, is one of 4 in phase 1, reaches primary completion later than 4 of the 21 other live ones, and was the 37th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:
University of Calgary · Sites in Belgium, Canada, Denmark and 4 more countries
Ages 18+ · Women only
Medicare Hospital (Pvt) Limited · Sites in Pakistan
Ages 18–45 · Women only
NYU Langone Health · Sites in United States
Ages 18–50 · Women only
Thomas Jefferson University · Sites in United States
Ages 16–55 · Women only
Ohio State University · Sites in United States
Ages 14–35 · Women only
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 13 · Phase 4 16
First in 2001; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 235 across the 52 interventional studies. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 52 have an industry lead sponsor. The 10 most frequent:
Anna Stanhewicz, PhD is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Anna Stanhewicz, PhD has 8 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
6 of the studies testing aspirin in Pre-Eclampsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT04479072University of ChicagoAspirin and Preeclampsia | 2026-12-01 |
| NCT07373756Dr. Sunita PunRandomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk Pregnant Women | 2026-12-31 |
| NCT06281665Malamo CountourisTreatment With Aspirin After Preeclampsia: TAP Trial | 2027-01-01 |
| NCT07041385Shalamar HospitalComparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 52 studies testing aspirin in Pre-Eclampsia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo pill taken once daily at bedtime for 12 weeks
Drug: Placebo
162mg aspirin taken once daily at bedtime for 12 weeks
Drug: Aspirin
162mg aspirin capsule
placebo capsule
magnitude of microvascular endothelial function
skin blood flow response to acetylcholine delivered via intradermal microdialysis
Time frame: baseline, 12 weeks
magnitude of brachial artery endothelial function
brachial artery flow mediated dilation
Time frame: baseline, 12 weeks
magnitude of microvascular endothelin-1 mediated constriction
skin blood flow response to endothelin-1 delivered via intradermal microdialysis
Time frame: baseline, 12 weeks
magnitude of microvascular nitric oxide-dependent dilation
skin blood flow response to acetylcholine + L-NAME delivered via intradermal microdialysis
Time frame: baseline, 12 weeks
Ran from Nov 2023 to primary completion in Jun 2026, 31 months.
Of 20 phase 1 interventional studies under Pre-Eclampsia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 31 months is above that.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Feb 2027, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin
Anna Stanhewicz, PhD